Pharmaceuticals Related News
How psychostimulants can damage dopamine production
Researchers from MedUni Vienna have identified the mechanisms behind the unwanted effects of psychostimulants, which are used to treat neuropsychiatric disorders.
Psychostimulants interact with dopamine...
EU regulation does not consider environmental emissions of pharmaceuticals
New research reveals that EU regulation is not currently considering the environmental emissions of pharmaceuticals in global manufacturing supply chains.
The EU regulation that covers...
Can ketamine help treat severe alcohol disorder?
A new trial from the University of Exeter will investigate whether ketamine-assisted therapy could help treat alcohol disorder.
The £2.4 million trial will be delivered...
Extracting medicinal mushrooms
As a result of the rising demand for therapeutic medications, medicinal mushrooms have become increasingly important in healthcare over the last ten years.
The rapid...
Blood thinning medication does not help COVID-19 recovery
Blood thinning medication does not help patients recovering from COVID-19, despite being offered to patients, according to research from the University of Cambridge.
Over 1,000...
Anti-cholesterol and diabetes drugs may reduce the risk of eye disease
Regularly taking anti-cholesterol and diabetes drugs may lessen the risk of degenerative eye disease associated with ageing, according to new research.
Findings from a pooled...
Bivalirudin is the safest treatment for percutaneous coronary intervention
Researchers have found that bivalirudin is a safer and more effective anticoagulant than heparin for treating percutaneous coronary intervention patients.
The researchers found that heart...
New Marfan syndrome treatment could delay the need for surgery
A new Marfan syndrome treatment could delay the need for surgery and reduce aortic root size in patients, according to research presented at the...
Big Boost for NervGen’s Phase II Clinical Trials
In a groundbreaking development for paralysed people, the revolutionary NVG-291 treatment for spinal cord injury is set to undergo Phase II clinical trials in...
NervGen: A new hope for treating spinal cord injuries
For decades, medical researchers have struggled in vain to solve the mystery of how to reverse paralysis caused by serious spinal cord injuries.
Finally, hope...
AccumTM variants successfully increase breast cancer treatment potency
Biotechnology experts Defence Therapeutics have revealed strong in vitro results of its AccumTM variants on the ADC breast cancer treatment called Enhertu® (fam-trastuzumab-deruxtecan-nxki), which...
Defence Therapeutics prepares to test its DC cancer vaccine against melanoma
Defence Therapeutics is finalising all required steps in preparation for a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer...
Defence Therapeutics embark on next stage of breast cancer treatment development
In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase...
Defence Therapeutics’ new COVID vaccine achieves successful testing
Biotechnology experts Defence Therapeutics have sensationally announced that their new COVID vaccine has demonstrated effectiveness in a non-rodent model.
The new COVID vaccine – called...
Commonly prescribed gout medication found effective against COVID-19
A conventional gout medication that is utilised widely around the world has proven to be effective at combatting COVID-19, potentially adding a new weapon...
AstraZeneca treatment unsuccessful at preventing symptomatic COVID-19
AstraZeneca’s antibody treatment – AZD7442 – has been unsuccessful in preventing symptomatic COVID-19 in patients recently exposed to the SARS-CoV-2 virus.
The results of AstraZeneca’s...
Improving communication and collaboration around vaccines
Alison Maassen and Alba Godfrey of EuroHealthNet explain the importance of the IMMUNION project in improving public knowledge and confidence around vaccines.
Vaccines are a...
Cancer vaccine shows long-lasting anti-tumoural response
A pre-clinical study has demonstrated the anti-tumoural efficacy of the AccuVAC-D001 cancer vaccine.
Developed by biotechnology company Defence Therapeutics Inc., the AccuVAC-D001 cancer vaccine demonstrated...
Study shows newborns with seizures may be overmedicated
A new study has shown that babies on long-term antiseizure medication may be overmedicated, as continued administration of the medicines may not prevent continued...
Improved treatment for miscarriage more cost-effective for NHS
A new drug combination that is better at treating ‘silent’ miscarriages than the currently used NHS treatment is more cost-effective, according to a new...
